Agoracom Blog Home

Archive for the ‘Hollister Biosciences’ Category

Hollister Biosciences Inc. $HOLL.ca and Heavy Brands Inc. Enter into Letter of Intent for Proposed Joint Venture Agreement $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:16 AM on Wednesday, August 5th, 2020
  • Announced that it’s entered into a letter of intent to manufacture pre-rolls for some of the biggest names in rock and metal music
  • Under the terms of the Agreement, Heavy intends to license its Heavy Grass brand for use by Hollister in connection with branding, production and sale of cannabis products primarily via collaborations with its roster of music artists
  • Hollister will grant to Heavy a limited license for use of its HashBone brand for incorporation into any packaging and/or logo design of products. Heavy will retain ownership of all co-brand designs

VANCOUVER, BC, Aug. 5, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company”, “Hollister Cannabis Co.” or “Hollister”) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona, is pleased to announce that it has entered into a letter of intent (the “LOI”) to complete a Definitive Agreement (the “Agreement”) with Heavy Brands Inc. (“Heavy”), a rock and heavy metal lifestyle cannabis branding company.

Under the terms of the Agreement, Heavy intends to license its Heavy Grass brand for use by Hollister in connection with branding, production and sale of cannabis products primarily via collaborations with its roster of music artists. Hollister will grant to Heavy a limited license for use of its HashBone brand for incorporation into any packaging and/or logo design of products. Heavy will retain ownership of all co-brand designs.

Products will be introduced in time and will include separate product branding. Heavy will lead the marketing initiatives of the new products leveraging their unique access to the live music industry.  

Heavy-Hollister co-brand products will be distributed exclusively by Hollister’s distribution partner, Indus Holdings Inc. (CSE: INDS), with the first product anticipated to be ready for distribution by October 1, 2020.

When asked about the Agreement, Dez Mitchell, head of Product Development from Heavy shared: “We are so thrilled to begin our partnership with Hollister and cannot wait to launch our first products together this fall.  For our Heavy Grass family, music and cannabis go hand in hand.  We have been fortunate to get to know Carl and his team over the last year and they have proven to uniquely understand our vision.  We are excited to show the world what we’ve been working on together.”

CEO of Hollister Biosciences, Carl Saling, also shared: “Music and cannabis have gone together for so many years; and lately, for the most part, it’s been all connected to rap and hip hop. I have always wanted to bring more attention to cannabis and connect with fans of heavy metal in a truly authentic way.

We have big things in store for our initial launch, and looking forward to many awesome rock and metal collaborations that Hollister and Heavy Grass will be bringing to market.”

About Heavy Brands

Heavy Brands Inc. is a Southern California lifestyle cannabis branding and marketing company building globally recognized cannabis lifestyle brands based in Los Angeles.  It’s flagship brand, Heavy Grass, has grown organically by connecting hard rock and heavy metal fans to cannabis products that speak to their lifestyle.  Additionally, Heavy Grass releases a seasonal line of apparel that is worn by some of the largest rock artists and fans around the world.

Website: https://getheavy.com/

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The CSE has not in any way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Hollister Biosciences $HOLL.ca Provides Update on Q2 2020, Generated Record Quarterly Revenue of CDN$ 11.5 Million and Announces Distribution License Renewal $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:05 PM on Tuesday, July 14th, 2020
  • Generated record quarterly revenue of CDN$ 11.5 million,
  • CDN$ 1.375 million in EBITDA
  • Bureau of Cannabis Control officially renewed its cannabis distribution license for the next year through August 2021

VANCOUVER, BC, July 14, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona,  is pleased to provide an update on its Q2, 2020 performance as well as announce that the Bureau of Cannabis Control (“BCC“) officially renewed its cannabis distribution license for the next year through August 2021.

Q2 2020 Update

For the period beginning April 1st, 2020 and ending June 30th, 2020, Hollister reports that it generated record quarterly revenue of CDN$ 11.5 million and CDN$ 1.375 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products.  The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.

“We are very pleased with our revenue growth year to date.  Sales of cannabis related products have proven to be resilient throughout the COVID-19 pandemic.  We hope to continue to deliver strong results as the year progresses” stated Carl Saling, CEO.

About the BCC

The Bureau of Cannabis Control is the lead agency in regulating commercial cannabis licenses for medical and adult-use cannabis in California. The BCC is responsible for licensing retailers, distributors, testing laboratories, microbusinesses, and temporary cannabis events. A distributor (Type 11) licensee is responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, and conducting the quality assurance review of cannabis goods to ensure compliance with all packaging and labeling requirements. A licensed distributor may only distribute cannabis goods, cannabis accessories, and licensees’ branded merchandise or promotional materials.

“Our distribution license is a critical component to our California operation, and we are honored to have had our license renewed by the BCC” stated Carl Saling, CEO.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Hollister Biosciences Inc. $HOLL.ca and Allied Corp. sign Definitive Agreement for Distribution of Products Under Veteran Based Brand: Tactical Relief™ $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:12 AM on Friday, June 26th, 2020
  • Announced definitive agreement with Allied Corp. to manufacture and distribute throughout California products targeted at veterans and first responders under the brand Tactical Relief ™
  • The first products to be manufactured will feature products that are recognized for their medicinal properties in the treatment of Post Traumatic Stress Disorder (PTSD)

VANCOUVER, British Columbia, June 26, 2020 — Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB) (the “Company” or “Hollister”) is pleased to announce that further to the press release dated February 7th, 2020, through it’s subsidiary, Hollister Cannabis Co.  has on June 22nd, 2020 signed a definitive agreement (the “Agreement”) to bring to market with Allied Corp. (“Allied”) a pipeline of products that are targeted towards helping veterans and first responders. These products will be brought to market under the brand Tactical Relief™, a veteran-founded hemp-based CBD oil brand owned by Allied Corp. (OTCQB: ALID).

Branded under Tactical Relief™, the first products to be manufactured will feature products that are recognized for their medicinal properties in the treatment of Post Traumatic Stress Disorder (PTSD). True to Hollister’s mission, the products will be crafted in small, artisanal batches for optimal quality and made from premium California-grown cannabis.

Under the terms of the Agreement, Allied will contribute the Tactical Relief™ brand support including use of trademark, artwork, logos and package design for a series of products. On an ongoing basis, Allied will be financially responsible for all marketing design and support. Hollister will be responsible for all aspects of production and procurement of underlying materials. Hollister will also be responsible for all costs associated with distribution and sales support.  All production of cannabis products will take place under Hollister’s supervision and licenses. Allied and Hollister will further explore the development and marketing of additional products, as well as expanding into additional regions within the United States over the coming years.

The new Tactical Relief™ products will be distributed exclusively by Hollister’s distribution partner, Indus Holdings Inc. (CSE: INDS), and is anticipated to be in retail locations throughout California within quarter three of 2020. An estimated 5% of net profits from all sales will be donated to charity.  The remaining revenue generated from the sale of the products will be shared 60:40 between Hollister and Allied.

“This partnership is one that unites two powerful companies in the cannabis space with one common mission: to help veterans and first responders change the way they manage PTSD and TBI. This is a huge shift that has to happen nationwide. This partnership is the start of that shift,” said Adam Smith, VP Natural Health at Allied Corp.

Carl Saling, Hollister’s CEO stated: “We are thrilled to be working with Allied Corp. to bring much needed relief to our amazing veterans and 1st responders with PTSD and other ailments. This is a very important mission for Hollister to be able to have a huge impact on our veteran’s lives.”

About the Tactical Relief™  Brand

Led by a Green Beret and trainer of law enforcement, the Tactical Relief™ brand creates, promotes and sells high quality and patriotic CBD oils throughout the country. Allied’s CBD oils are full spectrum and are currently made from the highest quality hemp grown in Kentucky. Adam Smith (VP of Natural Health for Allied Corp.) is a Green Beret with nearly 17 years in service and experienced firsthand how CBD can help veterans and active-duty (military and first responders) ease their physical and mental stress due to post traumatic stress disorder and traumatic brain injury. Tactical Relief™ is on a mission to end the stigma around hemp and cannabis products, and to provide relief to as many service members as possible.

Website: https://tacticalrelief.com/

About Allied Corp.

Allied Corp. is an international medical cannabis production company with a mission to address today’s medical issues with a primary focus on Post Traumatic Stress Disorder in veterans and first responders. Allied helps those who have served by researching, developing and producing targeted cannabinoid health solutions for those who need them. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.

For more information on Allied Corp., visit www.allied.health

Investor Relations for Allied:
[email protected]
1-877-255-4337

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a California based vertically integrated cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality California-grown cannabis and hemp products. Hollister uses a vertically integrated, high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker.”

Website: www.hollistercannabisco.com

HOLLISTER BIOSCIENCES INC.:

Company Contact:

[email protected]
Tel: 604-961-0296

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Hollister Bioscience’s $HOLL.ca 100% Owned Subsidiary #Venom Extracts Generates Record Monthly Revenue of $3.75 million CDN in May 2020 $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:18 AM on Thursday, June 11th, 2020
  • For the month of May 2020, Venom reports that it generated record revenue of CDN$ 3.75 million from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges, representing the highest revenue Venom has achieved in a single month
  • As compared to May 2019, Venom’s revenue increased 163%. 

VANCOUVER, BC, June 11, 2020 - Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) ( FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that its 100% owned subsidiary Venom Extracts (“Venom“) generated record revenue and EBITDA for the month of May 2020. 

For the month of May 2020, Venom reports that it generated record revenue of CDN$ 3.75 million from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges, representing the highest revenue Venom has achieved in a single month.  As compared to May 2019, Venom’s revenue increased 163%.  The Company cautions that revenue figures have not yet been audited and are based on reports prepared by Venom management.

“We are firing on all cylinders here at Venom” shared Jake Cohen, Founder of Venom Extracts.  “Having our best month ever in terms of revenue and EBITDA speaks to the resilience of our business model in the face of these uncertain times as well as the healthy customer demand for our product line.”

“We are very excited to see these record monthly revenues. We are looking forward to replicating Venom’s business model in our California facilities and beyond.” shared Carl Saling, CEO of Hollister Biosciences Inc.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Hollister Biosciences $HOLL.ca Subsidiary AlphaMind Brands Inc. Plans to Launch Initial Medicinal #Mushroom Based Product Line $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:10 AM on Thursday, June 4th, 2020
  • Announced that the Company’s 100% owned subsidiary, AlphaMind Brands Inc. plans to launch medicinal mushroom based capsule and powder product lines
  • Initial product line will consist of a blended and bottled powder and capsule consisting of powdered cordyceps, lion’s mane, oyster, reishi and shiitake medicinal mushroom varietals

VANCOUVER, BC, June 4, 2020 - Hollister Biosciences Inc. (CSE: HOLL) (OTCPINK: HSTRF) (Frankfurt: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that the Company’s 100% owned subsidiary, AlphaMind Brands Inc. (“AlphaMind”) plans to launch medicinal mushroom based capsule and powder product lines.

The initial product line will consist of a blended and bottled powder and capsule consisting of powdered cordyceps, lion’s mane, oyster, reishi and shiitake medicinal mushroom varietals.  The formulations for both products are unique and developed through research driven initiatives.  The health benefits that the capsules and powder intend to provide include but are not limited to anti-inflammatory, antioxidant, anti-aging, anti-microbial and immune system support. 

Raw materials for the product line have arrived at Alphamind’s manufacturing partner, Kirkman and have been sent off for third party testing.  Once the ingredients are approved, AlphaMind anticipates production can begin by mid-June with the aim of having the product line in the market by mid-July 2020. 

Dr. Nikos Apostolopoulos, CSO of AlphaMind shared, “Our AlphaMind five mushroom blend will be a game changer for both athletes and non-athletes alike. This ethically sourced and organically grown blend provides potent antioxidants, and anti-inflammatory responses, helping to improve and maximize performance as well as daily activities.”

About AlphaMind

Alphamind Brands is a Canada and US based growth stage company, that is developing a portfolio of certified legal mushroom based natural health products. It is also actively conducting R&D initiatives, led by Dr. Nikos C. Apostolopoulos, who is exploring psilocybin based pharmaceutical treatments.  The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate. 

About Hollister

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Hollister $HOLL.ca Launches Tommy Chong’s Cannabis 1:1 Full-Spectrum Elixir $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 11:06 AM on Wednesday, May 27th, 2020
  • Announced the tincture it is manufacturing and distributing for its partner, Tommy Chong’s Cannabis, is officially ready to hit the market
  • The tincture, branded Tommy Chong’s Cannabis™ 1:1 Full Spectrum Elixir, features a sweet berry flavor and 1:1 ratio of CBD to THC; for a total of 1000mg cannabinoids (500mg CBD and 500mg THC).
  • Tommy Chong’s Cannabis™ Full Spectrum Elixir 1:1, is being distributed exclusively by Hollister Cannabis Co.’s distribution partner, Indus Holdings, Inc. (CSE: INDS)

VANCOUVER, May 27, 2020 - Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce the tincture it is manufacturing and distributing for its partner, Tommy Chong’s Cannabis, is officially ready to hit the market.

The tincture, branded Tommy Chong’s Cannabis™ 1:1 Full Spectrum Elixir, features a sweet berry flavor and 1:1 ratio of CBD to THC; for a total of 1000mg cannabinoids (500mg CBD and 500mg THC). True to the manufacturing mission of Hollister Cannabis Co., this 1:1 tincture was crafted in small, artisanal batches for optimal quality and made from premium California-grown cannabis. 

The tincture, Tommy Chong’s Cannabis™ Full Spectrum Elixir 1:1, is being distributed exclusively by Hollister Cannabis Co.’s distribution partner, Indus Holdings, Inc. (CSE: INDS)

CEO of Hollister Biosciences, Carl Saling, shared: “We are thrilled to have Tommy Chong’s Full Spectrum Elixir at Indus’ distribution center, ready to distribute to dispensaries in California. I am super proud of our team – especially through this global pandemic. We have continued to push forward and release a legendary product for a true legend!”

About Tommy Chong’s Cannabis: 

As one-half of the legendary comedy duo Cheech & Chong, Tommy Chong helped pioneer a completely unique brand of comedy directed at the counterculture movement of the early ’70s. At the heart of this brand of entertainment was cannabis. On-screen and off Tommy became a vocal advocate for his favorite herb. In a time where cannabis had to be talked about in whispers, Tommy was a loud voice for the advocacy movement, working tirelessly to destigmatize the use of this healing plant. With the legalization of recreational cannabis, Tommy’s voice continues to ring out loudly, touting its benefits and place in society. Now, Tommy is thrilled to share that passion and knowledge of cannabis with the rest of the world. Using his lifelong connections in the industry, he has made it his personal mission to share the very best product available with his fans and fellow herb connoisseurs. If anyone knows weed, it’s Tommy. And now fans of comedy and cannabis alike can experience the strains and products that Tommy himself has hand-selected.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

People are choosing #cannabis over cocktails because it’s healthier – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:05 PM on Friday, May 15th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More

People are choosing cannabis over cocktails because it’s healthier

  • What’s a safer, healthier option to alcohol? That would be cannabis, say 90 per cent of Americans asked about their use of substances last year.
  • The findings seem to reflect that people trying to adopt healthier lifestyles are thinking cannabis could be a better fit than alcohol, suggests an article by Merry Jane.

By Angela Stelmakowich

A healthier lifestyle was among four factors associated with more people consuming weed in 2019 than in 2018. The other three factors include there being less stigma around cannabis, legalization and decriminalization efforts, and pot from legal U.S. states being sold on the black market in states where cannabis is still a no-no.

The National Cannabis Study, released last month by marketing research firm MRI-Simmons, notes the single-year jump in cannabis consumption between 2018 and 2019 was significant. About 22 per cent of surveyed Americans consumed weed at least once in 2019 compared to 16 per cent in 2018. That represents a 38 per cent hike.

Of those who used cannabis in 2019, the survey shows 17 per cent consumed once a month or more, while seven per cent consumed daily.

Cannabis, herbal supplements and vitamins were all up from 2018 to 2019. / Photo: Christopher Furlong/Getty Images Christopher Furlong/Getty Images

While consumption of cannabis, herbal supplements and vitamins were all up from 2018 to 2019, caffeine and alcohol consumption dropped slightly, both by about three per cent.

About 58 per cent of respondents also said that marijuana should be legal, up from 56 per cent in 2018, and almost two-thirds, 64 per cent, over the age of 18 expect marijuana to become legalized in all states within the next five years.

The study used a nationally representative online sample of more than 5,000 respondents.

Source: https://www.thegrowthop.com/cannabis-news/cannabis-continuing-to-mainstream-with-more-americans-using-weed-in-2019

Hollister Biosciences Inc. $HOLL.ca CEO Provides Corporate Update $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 9:27 PM on Wednesday, May 13th, 2020
  • “As the country begins to emerge from stay at home orders, we thought it would be prudent to provide our shareholders with an update on our operations and some additional details on our recently announced acquisitions, Alphamind and Venom Extracts.” Said Carl Saling, CEO Hollister. “Integration of the new companies is well underway and continues to run smoothly”

VANCOUVER, May 13, 2020  - Hollister Biosciences Inc. (CSE: HOLL, OTC: HSTRF,  FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to provide a Corporate Update from CEO, Carl Saling.

“As the country begins to emerge from stay at home orders, we thought it would be prudent to provide our shareholders with an update on our operations and some additional details on our recently announced acquisitions, Alphamind and Venom Extracts.” Said Carl Saling, CEO Hollister. “Integration of the new companies is well underway and continues to run smoothly”

COVID-19 (the “Pandemic”) Update

In many states across the country cannabis was deemed an essential business and Hollister has been able to stay operational in all the states in which it operates.

It has been a challenging environment; however, we have navigated the new environment effectively.  Some cities and counties only allowed curbside pick-up and or delivery of cannabis, while others have closed but others stayed completely open for business using and implementing safety precautions.

Hollister took action to help the communities in which they operate by manufacturing hand sanitizer and donated it to offices and front-line workers. As recognition for our efforts the county of Hollister, California awarded Hollister Cannabis Co. a Certificate of Appreciation for our support.

Today, Hollister’s facilities are operating under social distancing guidelines to ensure the Company’s employees are safe.  The Company has also provided employees with gloves, masks and hand sanitizer to take home.  It is the Company’s first order concern during the pandemic to ensure that employees are operating in a safe and healthy environment and provide them with the tools they need to keep themselves and their families safe.

Hollister Cannabis Co.

Hashbone, the Company’s bubble hash infused pre roll brand, continues to grow and gain new fans daily.  The Company introduced HashBone “Minis” which are 0.5 gram bubble hash infused pre-rolls packaged in a 5 pack. The Company has rolled out Hybrid and Sativa SKU’s now available in select California dispensaries. 

The Company also plans to introduce the HashBone “Wolfie”, which answers the call of the true connoisseur. The HashBone Wolfie is a traditional HashBone coated with full spectrum cannabis oil and rolled in bubble hash.  There is hash on the inside and hash on the outside with full spectrum oil holding them together.  The HashBone Wolfie is currently in the testing phase and estimated to be in the market before the end of May 2020. 

Strategic Alliances with Tommy Chong

Further to the news release dated February 7, 2020, the Company is pleased to disclose the strategic relationship with Tommy Chong is progressing well. Hollister is very close to launching its 1st SKU with Tommy Chong called Tommy Chong’s Cannabis Full Spectrum Elixir comprising a 1:1 ratio – 500mg CBD: 500mg THC.  The product has completed testing, labels are being generated, and the Company expects product launch before the end of May 2020.

Venom Extracts

Venom Extracts (“Venom“) continues to be integrated within Hollister Biosciences operations and the synergies are evident. Plans are underway for expansion of Venom into Hollister’s manufacturing facility in California with engineering and permitting processes underway.  The Company anticipates Venom will be producing in California in Q4 2020.

Throughout the pandemic, Venom products continued to see significant growth in demand which resulted in record revenue for Q1, 2020.  Although these numbers will be disclosed in Hollister’s Q1 report, only a small portion will be included in Hollister’s audited financial statements, as the acquisition closed on March 24, 2020 

AlphaMind

The integration process is underway pursuant to the Company’s recently announced acquisition of AlphaMind (see News release dated April 30, 2020).  The Company believes AlphaMind’s medicinal mushroom based product SKU’s will be complementary to Hollister’s existing product line.  AlphaMind has an agreement in place with an established US based manufacturing partner.  It is the Company’s intention to build out an e-commerce platform to market and distribute AlphaMind’s product line.  AlphaMind is a new entrant in the burgeoning medicinal mushroom sector and is also in the process of developing IP surrounding psilocybin based pharmaceutical treatments.

Future Objectives

The Company believes the pandemic has changed consumer behaviour, possibly in a permanent fashion. 

Hollister believes it can capitalize on this in several ways:

  • The company is looking to accelerate its direct to consumer platform for both the hemp and the cannabis markets.
  • Hollister Biosciences will look to build a centralized ecommerce management system that will streamline the sales and marketing of all Hollister Biosciences non cannabis brands like Rebel Hemp Company & AlphaMind.
  • The Company will continue to evaluate the changing cannabis regulatory landscape to expand operations into new states.
  • The Company will also evaluate new technologies which may be utilized in the Company’s Facilities in the future.
  • Hollister Cannabis Co. is currently in the design phase of expanding its facility to accommodate the Venom brand.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

CLIENT FEATURE: Hollister $HOLL.ca A Vertically Integrated Cannabis Co With Products In 220 California Dispensaries , JVs & Partnerships With Global Brands $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 4:49 PM on Wednesday, May 13th, 2020

Hollister Highlights Of Current Operations:

  • Hollister’s products are now present in 220 of 600 California dispensaries.
  • Own’s California’s #1 hash infused pre-roll “HashBone”
  • Vision is to capitalize on this success to become the sought after premium brand portfolio of Cannabis across multiple states and Hemp nationwide
  • Major LOI, Joint Ventures and Licensing Agreements Support Proof Of This Vision
  • “Easy Riders” – Milliions Of Global Followers
  • “Tactical Relief” – Veteran Founded, Hemp Based CBD Brand With Nation Wide Members  
  • “Tommy Chong” – Exclusive Manufacture & Distribution Of Tommy Chong’s Cannabis (TM) Full Spectrum Elixir 1:1

“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”. 

– Tommy Chong

2 Highly Accretive Acquisitions

Hollister Biosciences Closes Transformational Acquisition of Rapidly Growing Venom Extracts Adding Over $16.4 Million In 2019 Revenue and $2.5 Million in EBITDA

  • one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.

HIGHLY ACCRETIVE $20,000,000 ACQUISITION, ADDING OVER CDN$16.4 MILLION OF 2019 REVENUE

  • For the year ended December 31, 2019, management of Venom Extracts reports having generated over CDN$16.4 million in revenue and over CDN$2.5 million in EBITDA from its product line of cannabis concentrates and cartridges. 
  • Venom Extract’s management also reports a strong start to 2020 and is anticipating record Q1 revenue.

Hollister Biosciences Closes Acquisition of AlphaMind Brands Inc.

  • Alphamind Brands is developing a portfolio of certified legal mushroom based natural health products
  • The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate.

FULL DISCLOSURE: Hollister Biosciences Inc. is an advertising client of AGORA Internet Relations Corp.

How The #Cannabis Industry Is Coping In 2020 – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 9:45 PM on Sunday, May 10th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More

How The Cannabis Industry Is Coping In 2020

  • Canada and most U.S. states with legalized cannabis industries declared dispensaries as essential services, allowing sales to continue throughout the COVID-19 crisis, enabling robust demand to be met
  • Even with strong sales momentum, cannabis stocks broadly suffered during the quarter amid heightened market volatility
  • Early-stage cannabis companies rely heavily on external capital to fuel their growth ambitions, but investors are stepping back from financing riskier industries in the current environment
  • Despite these near-term challenges, we remain optimistic on the longer-term prospects for cannabis as its acceptance grows

Amid widespread COVID-19-related retail store closures, many cannabis dispensaries received “essential business” designations. This allowed cannabis consumers to stock up on medicinal and recreational cannabis, fueling strong sales figures despite a tumultuous Q1 2020. Yet, even with strong sales momentum, cannabis stocks broadly suffered during the quarter amid heightened market volatility. Early-stage cannabis companies rely heavily on external capital to fuel their growth ambitions, but investors are stepping back from financing riskier industries in the current environment. Some cannabis companies are now running low on cash, forcing them to sell stakes at undesirable valuations or scale back operations or staffing.

Despite these near-term challenges, we remain optimistic on the longer-term prospects for cannabis as its acceptance grows. New store openings and the sale of edibles are helping to fuel greater legal consumption. In addition, COVID-19’s economic impact is broadly hurting tax revenues at the local, state, and federal level, potentially providing greater impetus to legalize and tax cannabis. With only about 10% of cannabis sales occurring through legal channels, we believe there is substantial opportunity for continued growth across regulated channels.

Is Cannabis A Consumer Staple?

The COVID-19 crisis is plunging the global economy into recession, yet its impact will not be felt equally across industries. During recessions, consumers may forgo discretionary items like jewelry or electronics, but staples such as essential food and beverages tend to see robust sales. Historically, alcohol and tobacco exhibit staples-like characteristics, demonstrating strong sales despite economic weakness. During the global financial crisis, for example, alcohol consumption increased 7.2% in 2008-09 from 2006-07 levels, while total sales in the consumer discretionary sector fell by -9.35% over that time frame.1,2

Legalized cannabis did not exist during the Great Recession, but recent figures suggest cannabis sales share similar characteristics with alcohol and tobacco. Canada and most U.S. states with legalized cannabis industries declared dispensaries as essential services, allowing sales to continue throughout the COVID-19 crisis, enabling robust demand to be met.

  • Online cannabis purchases in Ontario have surged from 5,000 orders in mid-March to 9,000 orders by mid-April.3
  • Oregon’s cannabis sales increased 37% year over year in March, its highest single-month increase.4
  • Between March 16th and March 22nd, year-over-year sales of recreational cannabis across key US markets, including California, Colorado, Oregon and Alaska, were up 50%.5
  • One of Nevada’s largest cannabis delivery businesses reported a 400% increase in cannabis retail deliveries since March 20th.6

While lockdown may have accelerated cannabis demand, cannabis sales were already on an accelerating path. January and February sales numbers in Canada increased 181% year-over-year to C$154 million and 190% to C$150 million.7 Estimates from Cannabis Benchmarks for March sales show a spike to C$216 million, more than three times March 2019’s sales of C$59 million.8

The shift towards greater cannabis acceptance has spurred much of this growth. Cannabis consumers among the legal adult population in Canada grew to 63% at the end of 2019 from 54% in 2018.9

Canada’s new recreational cannabis market, dubbed Rec 2.0, is also fueling growth. Rec 2.0 officially launched at the end of 2019, almost a year after legalization in Canada. Before Rec 2.0, only dried flower and oil were products sold, but now the sale of cannabis beverages, edibles and vapes, among other forms, is permitted. Derivative formats like these account for almost half of sales in mature and developed markets such as Colorado, showing how Rec 2.0 could play a major role in accelerating cannabis sales in Canada. Aurora Cannabis (ACB), for example, recently mentioned that approximately 20% of total sales could come from Rec 2.0 products.10 OrganiGram Holdings (OGI) also reported new Rec 2.0 products to account for 13% of total revenue in its most recent quarter.11

New Store Openings Grow Legal Cannabis’s Market Share

Curbing illicit cannabis sales is on the agenda for many governments around the world. Globally, legal cannabis sales reached $15 billion at the end of 2019, which is less than 10% of the estimated total market of $160 billion.12 Such low penetration both demonstrates the growth opportunity ahead as well as highlights some of the challenges for the legal market. In Canada, for instance, limited dispensary licenses plays a major factor, as recreational cannabis sales per capita are highly correlated to the number of stores.

In Q1 2020, Canada opened 191 new stores, bringing its total to 806.13 Ontario, Canada’s most populous province, now has 52 stores, versus just 27 at the end of 2019. But the few dozen stores represent just four per 1 million people. For comparison, Colorado has 180 stores for every 1 million people.14 The store comparison between the two countries is notable, as further licenses should help meet consumer demand and promote greater legal sales.

Within the U.S., active dispensary licenses are up 5.5% year-to-date, with 385 new stores opening around the country.15 Yet, given that the US has nine times more dispensary licenses than Canada, more stores is a less critical factor than wider legalization across populous states or at the broader federal level.

Cannabis Industry Leveraging E-commerce To Further Grow Sales

Oftentimes, crises breed both new problems and new solutions. During this social distancing era, Colorado legalized online sales of recreational cannabis, fulfilling a longstanding request from cannabis companies.16 Cannabis consumers can now order, pay online and pick up at-store. A few other states – Massachusetts, Illinois, Michigan and Oregon – already allow cannabis e-commerce.

In Canada, the Alcohol and Gaming Commission of Ontario (AGCO) authorized cannabis retail stores to offer e-commerce solutions, starting April 7th.17 E-commerce authorization resulted from an emergency order by the Government of Ontario to deter illegal cannabis sales amid physical distance mandates. For now, the measure is temporary, but it includes the possibility of extension.

Financing Cannabis’s Growth

Early-stage industries tend to rely on the capital markets to fund growth. The phenomenon describes a healthy dynamic between those with capital to invest and those seeking capital for growth. The cannabis industry is particularly dependent on capital, as growing, harvesting, packaging and distribution require property, equipment and employees. With high growth expectations, cannabis companies tend to plow their freshly raised capital into various parts of the ecosystem, leaving little cash available to weather a storm. The constant need for new financing can expose weaker companies that may need to raise capital at undesirable terms, or worse, cannot raise additional capital at all.

HEXO Corp. (HEXO), for example, a leading cannabis grower in Canada, recently closed a C$46 million public offering but was forced to sell its equity 20% below its last traded price.18 Other larger players have followed suit, like Tilray (TLRY), which raised C$90 also at a 20% discount.19

There are companies, however, with strong cash positions that may be able to weather this challenging financing environment better than others. Canopy Growth Corp. (CGC) and Cronos Group (CRON) both have over $1 billion in cash & equivalents on their balance sheets. GW Pharmaceuticals (GWPH) holds over $500 million in cash & equivalents. Balance sheet strength allows these companies to potentially wait longer before needing to raise additional outside capital.

COVID-19 Could Expedite Cannabis Legalization

In our article “Themes for Defensive Positioning,” we highlighted that economic downturns can accelerate efforts to find new sources of economic stimulus and tax revenue. Legalizing (and taxing) recreational cannabis is one such avenue states could pursue given its track record of generating economic growth and taxes. Estimates hold that nationwide legalization in the U.S. could generate $132 billion in aggregate tax revenue and more than a million new jobs across the country by 2025.20 Such growth comes not from an unproven, speculative market, but from the conversion of a largely illicit market to a legal, regulated one. Such taxes and economic growth could be particularly welcome given stalling economic growth and swelling debt caused by COVID-19.

This year, several states could legalize recreational use. Virginia recently decriminalized cannabis, joining 27 other states that have taken such actions.21 The bill doesn’t legalize cannabis sales yet, but Virginia’s Governor is also clearing the path for easier access for medicinal uses.22 In New Jersey, lawmakers voted to add legalization to November’s ballot. Should the bill pass, it could add additional pressure to neighboring New York and Connecticut.

Illinois, where legalized cannabis went into effect in January, is the most recent model other states could follow. Illinois has the second-highest tax regime on cannabis sales in the country, where taxes vary from 10% to 25%.23 In Q1, Illinois cannabis stores sold $110 million, generating at least $11 million in tax revenues. Another benchmark is Colorado, which legalized cannabis in 2014. In Q1 2020, Colorado generated $79 million in tax revenue from cannabis-related sales.24 In 2019 alone, the state collected over $300 million in tax revenue, which was earmarked for cannabis regulation, research and schools.25

With a global recession looming, the economic benefits of legalized cannabis could be too enticing for states, provinces and countries to ignore.

Conclusion

The recent increase in cannabis sales in the U.S. and Canada since COVID-19 reflects the non-cyclical nature of cannabis sales. While some cannabis companies may struggle from lack of access to capital during this volatile period, the stronger ones could continue to see substantial growth as they meet robust consumer demand. Trends in new dispensary openings, a shift to e-commerce, and the introduction of new consumable forms of cannabis should further fuel growth across North America. Longer term, the potential for further legalization efforts amid the COVID-19 crisis should provide a tailwind to the industry.

Related ETFs

POTX: The Global X Cannabis ETF seeks to invest in companies across the cannabis industry. This includes companies involved in the legal production, growth and distribution of cannabis and industrial hemp, as well as those involved in providing financial services to the cannabis industry, pharmaceutical applications of cannabis, cannabidiol (i.e., CBD), or other related uses including but not limited to extracts, derivatives or synthetic versions.

Please click on the fund name for current holdings.

Footnotes

1. Jacob Bor, et al. “Alcohol Use During the Great Recession of 2008-2009,” January 29, 2013.

2. U.S. Census Bureau. Discretionary sales including retail sales of Motor Vehicles & Parts, Furnitures, Electronics & Appliances, Clothing, Sporting Goods, General Merchandise, and Miscellaneous Stores. Accessed on April 2020.

3. Cannabis Benchmarks, “Canada Cannabis Spot Index (CCSI)”, April 17, 2020.

4. Willamette Week, “Oregon Cannabis Sales in March Were the Highest Ever for a Single Month,” April 6, 2020.

5. New York Post, “Cannabis sales hit new highs in US and Canada,” March 24, 2020

6. Reno Gazette Journal, “Nevada marijuana deliveries are skyrocketing. Is this the new normal for the pot industry?,” March 30, 2020.

7. Statistics Canada, “Cannabis Stores Sales,” Accessed on April 2020.

8. Cannabis Benchmarks, (n3).

9. BDS Analytics, “How Will “Cannabis 2.0″ Affect the Legal Canadian Market?,” February 18, 2020.

10. Aurora Cannabis, “Q2 2020 Earnings Call Transcript,” February 13, 2020.

11. Organigram, “Organigram Reports Second Quarter Fiscal 2020 Results,” April 14, 2020.

12. Global X ETFs, “Introducing the Global X Cannabis ETF (POTX),” September 19, 2019.

13. Cannabis Benchmarks, (n3).

14. Note: According to CannabizMedia, Colorado has 1,038 active licenses. Per the U.S. Census Bureau, Colorado’s population is 5.759 million people.

15. CannabizMedia, “Cannacurio: Dispensary & Retailer Leaderboard (Q1 2020),” April 13, 2020.

16. The Colorado Sun, “Coronavirus fuels marijuana industry’s push for online sales, delivery in Colorado,” April 13, 2020.

17. Alcohol and Gaming Commission of Ontario, “Ontario Allows Cannabis Delivery and Curbside Pick-up from Authorized Retail Stores During COVID-19,” April 7, 2020.

18. Hexo Corp, “HEXO Corp. Closes $46 Million Underwritten Public Offering,” April 13, 2020.

19. Tilray, “Tilray, Inc. Announces Pricing of its $90.4 Million Registered Offering,” March 13, 2020.

20. The Washington Post, “Study: Legal marijuana could generate more than $132 billion in federal tax revenue and 1 million jobs,” January 10, 2018.

21. Leafly, “Virginia just decriminalized marijuana. Here’s what that means,” April 13, 2020.

22. Marijuana Moment, “Virginia Governor Urges Medical Marijuana Expansion As Amendment To Recently Approved Bill,” April 15, 2020.

23. Illinois Policy, “What you need to know about marijuana legalization in Illinois?,” January 1, 2020.

24. Colorado Department of Revenue, “Marijuana Tax Data,” April 2020.

25. Ibis.

Investing involves risk, including the possible loss of principal. The investable universe of companies in which POTX may invest may be limited. The Fund invests in securities of companies engaged in Healthcare and Pharmaceutical sectors. These sectors can be affected by government regulations, expiring patents, rapid product obsolescence, and intense industry competition. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. POTX is non-diversified.

POTX’s investments are concentrated in the cannabis industry, and the Fund may be susceptible to loss due to adverse occurrences affecting this industry. The cannabis industry is a very young, fast evolving industry with increased exposure to the risks associated with changes in applicable laws (including increased regulation, other rule changes, and related federal and state enforcement activities), as well as market developments, which may cause businesses to contract or close suddenly and negatively impact the value of securities held by the Fund. Cannabis Companies are subject to various laws and regulations that may differ at the state/local, federal and international level. These laws and regulations may significantly affect a Cannabis Company’s ability to secure financing and traditional banking services, impact the market for cannabis business sales and services, and set limitations on cannabis use, production, transportation, export and storage. The possession, use and importation of marijuana remains illegal under U.S. federal law. Federal law criminalizing the use of marijuana remains enforceable notwithstanding state laws that legalize its use for medicinal and recreational purposes. This conflict creates volatility and risk for all Cannabis Companies, and any stepped-up enforcement of marijuana laws by the federal government could adversely affect the value of the Fund’s investments. Given the uncertain nature of the regulation of the cannabis industry in the United States, the Fund’s investment in certain entities could, under unique circumstances, raise issues under one or more of those laws, and any investigation or prosecution related to those investments could result in expense and losses to the Fund.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Global X NAVs are calculated using prices as of 4:00 PM Eastern Time. The closing price is the Mid-Point between the Bid and Ask price as of the close of exchange. Closing price returns do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.

Source: https://seekingalpha.com/article/4343907-how-cannabis-industry-is-coping-in-2020